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Introduction {#sec1}
============

Endothelial cells have indispensable roles in the control of vascular function, the formation and extension of new blood vessels during angiogenesis, and the repair of damaged vessels ([@bib14], [@bib59], [@bib79]). In addition to their essential roles in vascular homeostasis and wound healing, they also promote the pathogenesis of various diseases ([@bib17], [@bib19], [@bib28], [@bib58], [@bib59], [@bib100]). Integral to physiological or pathological processes, such as development, reproduction, wound repair, and tumor growth, angiogenesis involves conversion of resting endothelial cells into activated cells that loose some endothelial characteristics, acquire the capacity to elongate and migrate, and organize themselves into endothelial tube-like structures and networks ([@bib14]). These changes are initiated and directed by extracellular growth and differentiation factors, as well as hormones that activate cell surface receptor signaling in endothelial cells that lead to changes in cell differentiation and behavior. Several of the strongly angiogenic factors, such as fibroblast growth factors and vascular endothelial growth factors (VEGFs), act through tyrosine kinase receptors ([@bib22]).

Insulin, a secreted hormone, plays essential roles in regulating glucose homeostasis, cell metabolism, as well as angiogenesis and is used as standard treatment of patients with type 1 and type 2 diabetes ([@bib28]). Functional insulin receptors are expressed on endothelial cells, enabling intracellular signaling responses to hormone ([@bib28]). Insulin acts through cell surface receptor tyrosine kinases, which, following receptor autophosphorylation, induce kinase pathways, most notably the MEK1/2-Erk MAPK pathway and the PI3K-Akt-mTOR pathway ([@bib101]). Among many responses, insulin generally promotes cell proliferation and survival and enhances protein synthesis and cell size ([@bib101]). Depending on the concentration and time of exposure, insulin also induces changes in the expression of a variety of genes that are therefore seen as insulin-responsive genes ([@bib97]). Consistent with the endocrine activity of insulin, endothelial cells represent a major cell population that is directly exposed to and responsive to insulin ([@bib28], [@bib58]). Insulin also induces angiogenic gene and cell responses and promotes angiogenesis in cell culture, *ex vivo* and *in vivo* ([@bib28]). Enhanced angiogenesis contributes to diabetes-associated complications, including diabetic retinopathy and nephropathy ([@bib28]), and impaired wound healing, a common problem in diabetics.

We previously documented that insulin induces a rapid increase in cell surface transforming growth factor β (TGF-β) receptors in fibroblasts and epithelial cells, through mobilization of receptors from intracellular vesicles in response to insulin-induced Akt activation ([@bib10]). Increased cell surface presentation of TGF-β receptors confers increased sensitivity to TGF-β, thus enhancing autocrine TGF-β signaling responses ([@bib10]), raising the possibility that the insulin-induced increase in autocrine TGF-β signaling participates in the cellular and gene expression response to insulin. Indeed, we showed that blocking TGF-β signaling attenuates or inhibits the insulin-induced expression of some genes in fibroblasts or epithelial cells ([@bib10]).

TGF-β, a secreted dimeric protein, stands as the prototype of a family of cytokines and differentiation factors that act through cell surface receptors that are distinct in nature from the growth-factor-activated tyrosine kinase receptors, and, accordingly, signal differently ([@bib40], [@bib93]). Specifically, TGF-β binds to and activates tetrameric cell surface complexes of two pairs of structurally related dual-specificity kinases, named the type II (TβRII) and type I (TβRI) receptors. Upon ligand binding, the activated type I receptors C-terminally phosphorylate and thus activate Smad2 and Smad3 as signaling mediators that, following translocation into the nucleus, combine with DNA binding, sequence-specific transcription factors, and other coregulators to activate or repress target genes. Consequently, these Smads directly control gene expression and reprogramming in response to TGF-β, depending on the physiological context and nature of target genes ([@bib40], [@bib81]). This underlying mechanism is at the basis of a plethora of biological activities of TGF-β, including growth inhibition of epithelial and endothelial cells ([@bib36], [@bib81]) and effects on cell differentiation of many cell types, including epithelial- and endothelial-mesenchymal transitions ([@bib37], [@bib63], [@bib104]). TGF-β is also essential for embryonic vascular development ([@bib26]) and induces angiogenic responses in several assays ([@bib20], [@bib111], [@bib115]), possibly in association with the TGF-β-induced, Smad3-mediated expression of the gene encoding VEGF-A ([@bib36]). TGF-β, however, has also been seen to inhibit angiogenesis, likely related to its growth inhibitory effects on endothelial cells ([@bib41]). Both TGF-β receptor types are required for embryonic vascular development ([@bib65], [@bib86]).

In the present study, we examined whether insulin enhances autocrine TGF-β signaling in primary human endothelial cells and evaluated whether insulin-induced angiogenic responses incorporate increased autocrine TGF-β signaling in response to insulin. To assess the contribution of TGF-β signaling, we used primarily two inhibitors of TGF-β signaling with different mechanism of actions. The small molecule TβRI kinase inhibitor SB431542 blocks TGF-β-induced Smad2 and Smad3 activation that directs changes in gene expression, whereas a neutralizing anti-TGF-β antibody prevents all three TGF-βs from binding to their receptors, thus inhibiting all TGF-β signaling. Using primary human umbilical vein endothelial cells (HUVECs) as a model, we found that insulin treatment increases TGF-β receptor levels at the cell surface, consequently enhancing autocrine TGF-β signaling, which is required for insulin-induced endothelial cell migration and contributes to invasion and tube formation. Similar observations were also made in lung microvascular endothelial cells. Transcriptome and single gene analyses revealed that elevated autocrine TGF-β signaling also contributes to insulin-induced gene responses that have been associated with the angiogenic response. Finally, elevated autocrine TGF-β signaling in response to insulin contributed to insulin-induced angiogenic responses in cell culture, *ex vivo* and *in vivo*. These results strengthen our appreciation that one endocrine stimulus, i.e., insulin, which is commonly used to treat diabetes, engages TGF-β/Smad signaling in its outcome. Our evidence that TGF-β signaling is integrated into cell responses to insulin may have substantial implications for our understanding of and therapeutic approaches to diabetes-associated pathologies.

Results {#sec2}
=======

Insulin Induces Increased TGF-β Receptor Levels at the Cell Surface and Enhances Autocrine TGF-β/Smad Signaling in Primary Endothelial Cells {#sec2.1}
--------------------------------------------------------------------------------------------------------------------------------------------

Since insulin induces a rapid increase in cell surface presentation of both the TβRI and TβRII receptors in NMuMG epithelial cells and mouse embryonic fibroblasts ([@bib10]), we evaluated the effect of this hormone on primary HUVECs. These cells express insulin receptors, as assessed by qRT-PCR and immunoblotting, and insulin treatment did not affect its expression levels ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Treatment of these cells with insulin, without addition of TGF-β, induced rapid increases in TβRI and TβRII levels at the plasma membrane without changes in their total abundance, as assessed by cell surface protein biotinylation ([Figure 1](#fig1){ref-type="fig"}A). Consistent with the notion that insulin-induced Akt signaling drives TGF-β receptor translocation to the cell surface, Akt VIII, a selective inhibitor of Akt1 and Akt2 activation ([@bib13], [@bib69], [@bib116]), prevented the insulin-induced increase of cell surface TβRI and TβRII in endothelial cells ([Figure 1](#fig1){ref-type="fig"}B). As shown before in fibroblasts ([@bib10]), insulin induced Akt-mediated phosphorylation of the Rab GTPase-activating protein AS160, which controls cell surface transport of TGF-β receptors ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Similar to the effects of insulin on HUVECs, insulin treatment of human microvascular lung endothelial cells (HMVEC-L), which also express the insulin receptor ([Figure S1](#mmc1){ref-type="supplementary-material"}A), also resulted in increased cell surface abundance of TβRI and TβRII ([Figure S1](#mmc1){ref-type="supplementary-material"}C).Figure 1Insulin Enhances TGF-β Receptor Abundance at the Plasma Membrane and Induces Smad2 and Smad3 Activation through Autocrine TGF-β Signaling(A and B) Immunoblot analyses of the TβRI and TβRII receptors in human umbilical vein endothelial cells (HUVECs), treated with 100 nM insulin, in the absence (A) or presence (B) of the Akt inhibitor AktVIII. The top two panels show the cell surface TβRI and TβRII receptors, affinity labeled by cell surface protein biotinylation, isolated by affinity adsorption to Neutravidin, and visualized by SDS-PAGE and immunoblotting. The lower panels show TβRI and TβRII in total cell lysates, with GAPDH as loading control. Inhibition of Akt activation prevents the insulin-induced increase in TβRI or TβRII abundance at the cell surface. Immunoblots are representative of three independent experiments. Control group (0) was without insulin for 540 min in starvation media.(C) HUVECs were treated with 100 nM insulin, with or without SB431542, for the indicated times, and Smad2 and Smad3 activation was assessed by immunoblotting for C-terminally phosphorylated Smad2 (pSmad2) or Smad3 (pSmad3). Control group (0) was without insulin for 360 min in starvation media. The changes in Smad2 or Smad3 phosphorylation are densitometrically shown on the right.(D) qRT-PCR of *SMAD7 and SERPINE1* mRNA expressed by cells treated with or without insulin (Ins) in the presence or absence of SB431542 (SB) for 90 min and normalized against *RPL19* mRNA.Error bars indicate standard error of means, based on four independent experiments. \*p \< 0.05. In panels A, B, and C: AP, affinity purification, IB, immunoblot.

Most cells in culture express low TGF-β receptor levels at the cell surface ([@bib78], [@bib109]), and their cell surface concentration determines the cell sensitivity to TGF-β and, thus, the level of TGF-β-induced Smad activation ([@bib10], [@bib70], [@bib109]). Consequently, autocrine TGF-β signaling, commonly observed in cultured cells, is enhanced when the cell surface receptor levels are increased ([@bib10], [@bib109]). We therefore evaluated whether insulin induces activation of Smad2 and Smad3 without addition of exogenous TGF-β, by immunoblotting for C-terminally phosphorylated Smad2 or Smad3. This was indeed the case in both HUVECs and microvascular endothelial cells ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}D). Smad2 and Smad3 activation in response to insulin was prevented by SB431542, a TβRI kinase inhibitor that blocks the activation of Smad2 and Smad3 ([@bib12], [@bib64]), as well as by LY2157299 (galunisertib), another inhibitor of the TβRI kinase, and to a lesser extent of the TβRII kinase, which also prevents TGF-β-induced Smad2 and Smad3 activation ([@bib11]) ([Figure S1](#mmc1){ref-type="supplementary-material"}E). These results indicate that insulin-induced activation of Smad2 and Smad3 depend on autocrine TGF-β signaling ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}D). The modest Smad activation suggested that insulin treatment might mildly activate TGF-β target genes. In agreement with this, insulin mildly but significantly induced the expression of *SMAD7* and *SERPINE1*, direct TGF-β/Smad3 target genes ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}F), and their induction was prevented by SB431542 ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}F) or LY2157299 ([Figure S1](#mmc1){ref-type="supplementary-material"}G).

Autocrine TGF-β Signaling Participates in the Insulin-Induced Angiogenic Gene Expression Program {#sec2.2}
------------------------------------------------------------------------------------------------

To examine whether the increased autocrine TGF-β responses participate in the insulin-induced gene expression program, we performed RNA sequencing (RNA-seq) analysis of HUVECs treated with or without insulin for 90 min in the absence or presence of SB431542. Changes in gene expression with a p \< 0.05 cutoff were assessed using GO-ELITE ([Tables S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, and [S3](#mmc4){ref-type="supplementary-material"}). We focused our attention on angiogenesis- and blood-vessel-associated gene responses.

The RNA-seq data showed that insulin induced an overall increase in the expression of genes associated with angiogenesis (GO: 0001525 with an average of 1.16-fold change, adjusted p = 0.045), vasculogenesis (GO: 0001570 with an average of 1.26-fold change, adjusted p = 0.110), and tube morphogenesis (GO: 0035239 with an average of 1.7 fold change, adjusted p = 0.045) ([Table S1](#mmc2){ref-type="supplementary-material"}). Enrichment analysis of the SB431542-treated group, in the absence of insulin, when compared with untreated cells, did not show enrichment for angiogenesis (GO: 0001525) but showed enrichment for genes associated with blood vessel development (GO: 0001568) and blood vessel morphogenesis (GO: 0048514) ([Table S2](#mmc3){ref-type="supplementary-material"}). Inhibition of TGF-β signaling using SB431542 resulted in overall decreases in the expression of genes associated with blood vessel development and morphogenesis of 0.58-fold (adjusted p = 0.032) and 0.63-fold (adjusted p = 0.01), respectively. Enrichment analysis, comparing the gene expression in response to insulin + SB431542 versus insulin, showed that addition of SB431542 to insulin conferred an overall 0.62-fold decrease in the expression of genes associated with blood vessel development (GO: 0001568, adjusted p = 0.014) ([Table S3](#mmc4){ref-type="supplementary-material"}). Furthermore, treatment with SB431542 resulted in an overall 0.54-fold decrease in the expression of the gene set associated with cell migration (GO:0016477, adjusted p = 0.014) ([Table S2](#mmc3){ref-type="supplementary-material"}), a process that is integral to angiogenesis and blood vessel development. Insulin also induced an overall 1.65-fold increase in gene expression associated with actin cytoskeleton organization (GO: 0030036, adjusted p = 0.022) ([Table S1](#mmc2){ref-type="supplementary-material"}), which is consistent with increased cytoskeleton remodeling during cell migration. Addition of SB431542 to insulin resulted in an overall decrease of 0.62-fold with adjusted p = 0.014, when compared with insulin treatment ([Table S3](#mmc4){ref-type="supplementary-material"}). These transcriptome analyses suggest that autocrine TGF-β/Smad signaling contributes to and integrates into insulin-induced angiogenic and blood vessel development gene responses.

TGF-β Signaling Participates in the Insulin-Induced Response of Target Genes {#sec2.3}
----------------------------------------------------------------------------

Based on the enrichment analyses ([Tables S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, and [S3](#mmc4){ref-type="supplementary-material"}), we next quantified the contribution of autocrine TGF-β signaling to the insulin-induced expression of several individual genes associated with angiogenesis ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). For this purpose, we evaluated the mRNA levels by qRT-PCR after 90 min and 6 h of insulin treatment, in the absence or presence of SB431542. The selected genes comprised genes encoding transcription factors, enzymes, and transmembrane receptors and secreted growth factors with relevance to angiogenesis. We observed different temporal patterns of induction among the genes analyzed. Some showed moderate induction in response to insulin that persisted or increased by 6 h, such as *SRF*, *RUNX1*, *PTGS2*, *HMOX1*, *TNFRSF12A*, and *GJA5* ([Figure 2](#fig2){ref-type="fig"}A). Other genes, however, showed transient induction at 90 min that diminished by 6 h. This is most apparent for the *ANGPTL4* and *PDGFA* genes ([Figure 2](#fig2){ref-type="fig"}A). Most genes examined showed a contribution of autocrine TGF-β signaling to the insulin response. In most cases, the insulin-induced mRNA expression was inhibited or attenuated when TGF-β signaling was blocked, indicating dependence on the elevated autocrine TGF-β signaling. In contrast, SB431542 enhanced the expression of *HMOX1* and *ANGPT2*, indicating that autocrine TGF-β signaling represses the induction of these two genes. These results are largely consistent with the RNA-seq data for both insulin-induced changes and the effect of TGF-β inhibition at 90 min and further illustrate that the induction of autocrine TGF-β signaling promotes or controls the insulin-induced gene responses.Figure 2Relative mRNA Levels of Selected Genes, Encoding Transcription Factors, Enzymes, Membrane Proteins, and Ligands or Secreted Proteins, Known to be Involved in Angiogenesis(A) mRNA expression of the indicated genes was measured using qRT-PCR, and values were normalized to *RPL19* mRNA. Error bars indicate standard error of the means, based on three independent experiments. Inhibition of TGF-β signaling using SB431542 (SB) repressed the insulin-induced changes of the mRNA expression of many but not all genes. The statistical significance was determined by Wilcoxon test; \*p \< 0.05, \*\*p \< 0.0083.(B) Selected disease and Bio function analysis using IPA comparing different treatment groups. Values are activation *Z* scores. *Z* score represents the IPA regulation trend (*Z* score \> 0: up-regulation \[blue\]; *Z* score \< 0: down-regulation \[red\]).

The identities of insulin-responsive genes regulated by autocrine TGF-β signaling are informative in assessing the role of TGF-β in insulin-induced angiogenic gene responses. Among the intracellular signaling effectors, the induction of cyclooxygenase-2 expression ([@bib45], [@bib102]), encoded by *PTGS2*, fully depended on TGF-β signaling, whereas the expression of heme-oxygenase 1 from the *HMOX1* gene ([@bib74]) was repressed by autocrine TGF-β signaling. Remarkably, the insulin-induced expression of transcription factors known to contribute to angiogenic responses, namely, SRF and RUNX1 ([@bib32], [@bib30], [@bib31], [@bib50], [@bib60], [@bib96]), depended on autocrine TGF-β signaling ([Figure 2](#fig2){ref-type="fig"}A). Equally if not more striking is the substantial role of the increased autocrine TGF-β signaling in the induction by insulin of genes encoding secreted cytokines that promote angiogenesis and vasculogenesis ([@bib6], [@bib16], [@bib67], [@bib85], [@bib88]; [@bib92]). Specifically, the insulin-induced expression of angiopoietin-like 4 (ANGPTL4) and PDGFA depended on TGF-β signaling, whereas autocrine TGF-β signaling repressed the expression of the secreted angiogenic factor angiopoietin-2 (ANGPT2) and the VEGF-related placental growth factor ([Figure 2](#fig2){ref-type="fig"}A). Finally, insulin-induced expression of the "TNF receptor-related weak inducer of apoptosis" (TWEAKR, encoded by *TNFRSF12A*), which also promotes angiogenesis ([@bib107]), also depended on TGF-β signaling. We also observed transcripts with little to no change in response to insulin or SB431542. *FLT1*, which encodes a VEGF receptor, and *MMP2* encoding matrix metalloprotease 2 and *ADAM15*, which associate with extracellular matrix remodeling, were some genes that showed little to no changes ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Although our data of differential *VEGFA* expression did not pass our p \< 0.05 cutoff in the enrichment analysis, insulin has been reported to increase *VEGFA* expression in certain cells ([@bib38], [@bib51], [@bib75], [@bib80]). Quantified using qRT-PCR, *VEGFA* mRNA was not increased by 90 min and was modestly increased by 6 h in response to 100 nM insulin ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Increasing the insulin concentration, however, revealed a concentration-dependent increase of *VEGFA* mRNA expression by 6 h, which fully depended on autocrine TGF-β/Smad signaling, as it was prevented by SB431542 ([Figure S2](#mmc1){ref-type="supplementary-material"}A and S2B). Addition of the pan-TGF-β neutralizing 1D11 antibody, which prevents ligand binding to its receptors, confirmed the participation of autocrine TGF-β signaling in insulin-induced expression changes of select target genes, similar to the addition of SB431542 but often less pronounced ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Together, these data further support the contribution and roles of TGF-β signaling in insulin-induced angiogenesis gene responses.

Ingenuity pathway analysis (IPA) of the RNA-seq data revealed activation as well as inhibition of states of "associated diseases and biological functions" ([Table S4](#mmc5){ref-type="supplementary-material"}). We focused our attention on five IPA-based biological functions that are altered in response to insulin and relevant to angiogenesis ([Figure 2](#fig2){ref-type="fig"}B). Insulin-activated transcripts included those associated with "cell migration," "cell movement," "invasion," as well as "angiogenesis" and "vasculogenesis." SB431542 in the absence of insulin inhibited gene responses associated with cell migration, movement, and invasion but activated those associated with angiogenesis and vasculogenesis, strongly suggesting that autocrine TGF-β signaling promotes cell migration and invasion and has an inhibitory effect on some genes associated with angiogenesis and vasculogenesis in HUVECs ([Table S4](#mmc5){ref-type="supplementary-material"}). Combining SB431542 with insulin resulted in repression of all five insulin-induced response groups, thus reflecting contributions of autocrine TGF-β signaling to the insulin responses of these functional groups of genes ([Figure 2](#fig2){ref-type="fig"}B).

Autocrine TGF-β Signaling Promotes Insulin-Induced Cell Migration {#sec2.4}
-----------------------------------------------------------------

Insulin has been shown to stimulate cell migration ([@bib10], [@bib52], [@bib72], [@bib98]), which is now also supported by our transcriptome analyses of insulin-treated endothelial cells ([Figure 2](#fig2){ref-type="fig"}B). Since endothelial cell migration is integral to the angiogenic response, we asked whether insulin promotes migration of primary HUVECs and whether the increased autocrine TGF-β signaling contributes to the insulin-induced migration response. Serum-starved cell monolayers were "wounded" by scratching and stimulated for 8 h with insulin in the presence or absence of SB431542 or the TGF-β neutralizing antibody 1D11. Insulin promoted endothelial cell migration, scored by measuring the width of the cell-free wound before and after treatment ([Figure 3](#fig3){ref-type="fig"}A). The TβRI kinase inhibitors SB431542 and LY2157299 and the 1D11 anti-TGF-β antibody prevented the insulin-induced cell migration ([Figures 3](#fig3){ref-type="fig"}A, 3B, and [S3](#mmc1){ref-type="supplementary-material"}A). No differences in cell number were apparent after the 8 h time interval used to score cell migration ([Figure S3](#mmc1){ref-type="supplementary-material"}B). As in HUVECs, LY2157299, SB431542, and the 1D11 antibody also blocked the insulin-induced migratory response of microvascular endothelial cells ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3C).Figure 3Contribution of TGF-β Signaling to Insulin-Induced Cell Migration and Invasion(A--C) Migration of HUVECs measured in a monolayer wounding assay. Confluent monolayers were scratched with a pipette tip at time 0 and cells were allowed to migrate into the wounded area for 8 h, in the presence or absence of insulin with or without SB431542 (A and B) or the neutralizing anti-TGF-β antibody 1D11 (C). The migration distance is graphically presented. Error bars indicate standard error of the means of three experiments. The statistical significance was determined by Wilcoxon test; \*p \< 0.05, \*\*p \< 0.0083.(D and E) mRNA expression of *RHOB*, encoding a Rho-related GTP-binding protein, *SNAI1* and *SNAI2* (D), as well as *CDH5*, encoding VE-cadherin and *FN,* encoding fibronectin (E), after 90 min or 6 h insulin treatment, in the presence or absence of SB431542, determined by qRT-PCR and normalized against *RPL19* mRNA. Statistical significance was determined by Wilcoxon test; \*p \< 0.05, \*\*p \< 0.0083. Ab, antibody.(F) Immunoblots of extracted HUVEC lysates treated for 48 h in the presence or absence of insulin with or without SB431542. Protein expression changes were assessed by immunoblotting for Snail2, N-cadherin, VE-cadherin, and fibronectin, with GAPDH as loading control. IB, immunoblot.(G) Invasion of HUVECs in Transwell assays in the presence or absence of insulin, with or without SB431542 or 1D11 antibody. HUVECs were treated with insulin with or without SB431542 or the anti-TGF-β neutralizing antibody 1D11 for 8 h, and the invaded cells at the bottom filter surface were DAPI-stained and counted. The microscopic fields show cells that invaded through the filter as black dots against a white background. The results, shown graphically, are averages of five random microscopic fields of three separate experiments, each conducted in duplicate.Scale bar, 100 μM. Statistical significance was determined by Wilcoxon test; \*p \< 0.05, \*\*p \< 0.0083. ns, non-significant. SB, SB431542. Ins, insulin.

We also observed concomitant increases in the expression of several genes that might contribute to the increased cell migration. qRT-PCR analyses showed that insulin enhanced the expression of *RHOB*, a gene implicated in activation of cell migration ([@bib44]) after 6 h, albeit not yet at 90 min, and this increase was prevented when TGF-β signaling was blocked using SB431542 ([Figure 3](#fig3){ref-type="fig"}D). Insulin also induced the expression of *SNAI1* and *SNAI2* ([Figures 3](#fig3){ref-type="fig"}D and 3F), which are known to drive the process of endothelial-mesenchymal transition that enables the cells to acquire a migratory and invasive phenotype ([@bib63]). We also observed an increased fibronectin mRNA expression, consistent with initiation of endothelial-mesenchymal transition, although decreased VE-cadherin mRNA expression was not yet apparent after 6 h of insulin ([Figure 3](#fig3){ref-type="fig"}E). That the cells undergo at least a partial endothelial-mesenchymal transition is more apparent after 48 h of insulin treatment, which resulted in increased fibronectin and N-cadherin expression and decreased VE-cadherin expression ([Figure 3](#fig3){ref-type="fig"}F). The insulin-induced increase in RhoB expression and changes in the expression of genes that characterize endothelial-mesenchymal transition were prevented in the presence of SB431542 ([Figures 3](#fig3){ref-type="fig"}D--3F), indicating contributions of autocrine TGF-β signaling. These data strongly suggest that insulin-stimulated cell migration requires autocrine TGF-β signaling and is facilitated by changes in gene expression that mark endothelial-mesenchymal transition and are induced by the insulin-induced increase in autocrine TGF-β signaling.

We also evaluated whether TGF-β signaling plays a role in insulin-induced invasion of HUVECs using Transwell assays that quantify the number of cells that invade through extracellular matrix (™Matrigel) ([Figure 3](#fig3){ref-type="fig"}G). Cells were treated for 8 h with or without insulin in the absence or presence of SB431542 or the 1D11 antibody, and in the presence of mitomycin C, which was added to inhibit cell proliferation ([@bib21], [@bib108]). Addition of mitomycin C did not affect TGF-β-induced Smad activation and gene expression ([Figure S3](#mmc1){ref-type="supplementary-material"}D). In the presence of insulin, the number of invading cells increased about 2-fold compared with control treatment ([Figure 3](#fig3){ref-type="fig"}G). Both the 1D11 antibody and SB431542 prevented insulin to enhance cell invasion, although SB431542 treatment resulted in an increased number of invading cells ([Figure 3](#fig3){ref-type="fig"}G). As with SB431542, inhibiting TGF-β signaling using LY2157299 also prevented an insulin-induced increase in cell invasion and induced a higher basal cell invasion ([Figure S3](#mmc1){ref-type="supplementary-material"}E). These data suggest that insulin-induced autocrine TGF-β signaling participates in insulin-induced endothelial cell invasion, consistent with its role in cell migration and the insulin-induced cell plasticity response.

In endothelial cells, the type I receptor ALK1, also known as ACVRL1, has been shown to contribute to cell migration ([@bib23], [@bib62]) and to also be activated by TGF-β ([@bib35]). We therefore evaluated the contribution of ALK1 to the insulin response. Insulin induces a mild increase of ALK1 at the cell surface with no change in mRNA expression ([Figures S3](#mmc1){ref-type="supplementary-material"}F and S3G). However, this increase did not result in increased expression of *ID1*, a TGF-β-inducible ALK1 target gene ([Figure S3](#mmc1){ref-type="supplementary-material"}G). Inhibition of ALK1 and related BMP-responsive type I receptors using LDN-193189 enhanced the basal level of cell migration and invasion and allowed insulin to decrease endothelial cell migration, without a significant effect on cell invasion ([Figure S3](#mmc1){ref-type="supplementary-material"}H). These data suggest that ALK1 might participate in the insulin-induced cell migration response.

TGF-β Signaling Participates in Insulin-Induced Endothelial Network Formation in Culture {#sec2.5}
----------------------------------------------------------------------------------------

The ability of extracellular factors to control angiogenesis is often scored using a cell culture assay for endothelial network formation. In this assay, HUVECs, cultured on Matrigel, differentiate gradually with formation of cell adhesion junction complexes and form tube-like structures that connect to each other through node- and mesh-like structures ([@bib5], [@bib24]). Insulin has been shown to promote the formation of such an endothelial network when the endothelial cells are cultured in Matrigel. To examine whether autocrine TGF-β signaling contributes to the insulin-induced network formation, we performed these assays using HUVECs in the presence or absence of the TβRI kinase inhibitor SB431542 or the 1D11 antibody ([Figure 4](#fig4){ref-type="fig"}).Figure 4Effects of Inhibiting TGF-β Signaling in Insulin-Induced Endothelial Network Formation(A) HUVECs were plated onto Matrigel with or without insulin in the absence or presence of SB431542. Representative images are shown after 6 h of treatment.(B and C) Quantitative analyses of numbers of nodes (red) and meshes (blue), relative to untreated controls, in experiments with or without SB431542 (B) or 1D11 antibody (C).Error bars represent mean ± SEM of three independent experiments. Statistical significance was determined by Wilcoxon test; \*p \< 0.05, \*\*p \< 0.0083, \*\*\*p \< 0.0001. Scale bar, 500 μM.

Besides visible changes in appearance, the formation of the network can be quantified using several parameters, most notably the number of nodes and meshes formed ([Figure 4](#fig4){ref-type="fig"}A). Insulin significantly enhanced the total number of nodes and meshes ([Figures 4](#fig4){ref-type="fig"}B and 4C), thus promoting network formation. Addition of SB431542 or the 1D11 antibody augmented these parameters of network formation, both in the absence or presence of insulin, although the antibody was less effective ([Figures 4](#fig4){ref-type="fig"}B and 4C). These results strongly suggest that autocrine TGF-β signaling dampens the basal and insulin-induced network formation and further illustrate the functional cross talk between the insulin-induced increase in autocrine TGF-β signaling and a response to insulin that is not secondary to TGF-β signaling.

Insulin and SB431542 Control Intersomitic Vessel Development in Zebrafish Embryos {#sec2.6}
---------------------------------------------------------------------------------

Since insulin and inhibition of TGF-β signaling both enhanced the formation of endothelial tube-like structures in culture, we evaluated the effects of insulin and SB431542 on the development of the vasculature in transgenic *fli:gfp* zebrafish embryos ([@bib66]), in which endothelial cells express GFP and therefore are readily visible in the transparent embryos ([Figure 5](#fig5){ref-type="fig"}A). This *in vivo* model allows easy visualization of vascular patterning defects, especially since the vasculature of the trunk has an extremely regular pattern. Incubation of zebrafish embryos with high glucose results in the development of an additional vessel arising from the intersegmental vessel (ISV), and inhibiting Akt activation prevents this hyperbranching effect ([@bib53]). To follow changes in glucose levels and effects of insulin, we analyzed the expression of phosphoenol-pyruvate carboxykinase 1 (PCK1), which is transcriptionally repressed in response to insulin and therefore a sensitive marker of blood glucose levels ([@bib27]). This surrogate marker approach was necessary since the small amount of larval blood available precludes accurate analysis of insulin-induced changes in blood glucose levels. Adding insulin inhibited PCK1 expression ([Figure 5](#fig5){ref-type="fig"}B), illustrating the response to insulin.Figure 5Effects of Insulin and SB431542 on Intersomitic Vessels in Zebrafish Embryos(A) Scheme representing the treatment protocol. *Tg(fli:gfp)* zebrafish embryos were treated for 72 h.(B) Expression of *pck1* mRNA was quantified by qRT-PCR. RNA was extracted from pool of larvae that had received insulin with DMSO or DMSO control for 48 h.(C) Altered blood vessels in insulin- and SB431542-treated embryos. Representative images show the trunk vasculature of 96 hpf *tg(fli:EGFP)* zebrafish larvae. The boxes mark the region shown at higher magnification in the lower right corner of the panel.(D) Branching quantification of zebrafish blood vessels at 96 hpf, as seen in C in control solution DMSO, SB431542, insulin, and insulin + SB431542. Bars represent mean ± SD. Zf, zebrafish. Ctrl, control.

In this system, insulin treatment for 96 h induced hyper-branching of blood vessels, which appear as small vessel structures that sprout from the intersomitic vessels and grow horizontally toward neighboring intersomitic vessels ([Figure 5](#fig5){ref-type="fig"}C). This effect was similar to that of high glucose treatment ([@bib53]). Inhibiting TGF-β signaling for 96 h using SB431542 induced the formation of misdirected small vessels that emerged from the upper part of the intersomitic vessels, whereas combining insulin with SB431542 resulted in both extra branching and misdirected vessels ([Figures 5](#fig5){ref-type="fig"}C and 5D). Even though our data support an angiogenic response to insulin, we could not dissect the direct contribution of TGF-β signaling to the insulin-induced intersomitic vessel sprouting. The changes in the vascular pattern when TGF-β signaling is inhibited suggest a role of TGF-β signaling during early embryo vessel formation that is independent of insulin-induced blood vessel hyper-branching.

Blocking TGF-β Signaling Inhibits Insulin-Induced Microvessel Outgrowth from Neonatal Aortic Rings {#sec2.7}
--------------------------------------------------------------------------------------------------

In addition to analysis in the zebrafish model, we evaluated the contribution of TGF-β signaling to insulin-induced microvessel outgrowth *ex vivo*, following tissue explant of neonatal mouse aortae, using an aortic ring assay ([@bib9]) ([Figure 6](#fig6){ref-type="fig"}A). This assay relies on the capacity of the aortic explants to form new endothelial microvessels, whose outgrowth involves interactions of different cell types, including endothelial cells, pericytes, fibroblasts, macrophages, and dendritic cells ([@bib83]). In this assay, 1 mm transverse sections of aortae of 6-day-old mice are incubated in Matrigel for 96 h, allowing outgrowth of endothelial cells from the intimal layer. Consistent with its angiogenic effects, insulin stimulated microvessel sprouting from aortic rings that was more extensive than sprouting seen from control-treated aortae ([Figures 6](#fig6){ref-type="fig"}B and 6C). The insulin-promoted new microvessels were endothelial in nature, apparent by mTomato expression from the *Cdh5* promoter ([Figure S4](#mmc1){ref-type="supplementary-material"}), and their outgrowth was strongly attenuated in the presence of SB431542. Basal microvessel sprouting was minimal without addition of insulin, and SB431542 had no significant effect in reducing it ([Figures 6](#fig6){ref-type="fig"}B and 6C). A pan-neutralizing anti-TGF-β antibody that prevents receptor binding of all three TGF-β ligands also decreased insulin-induced microvessel outgrowth from aortic rings, whereas non-immune IgG had no effect ([Figures 6](#fig6){ref-type="fig"}B and 6C). These findings indicate that autocrine TGF-β/Smad signaling participates in and contributes to the angiogenic activity of insulin in the microvessel outgrowth assay.Figure 6Contribution of TGF-β Signaling in Insulin-Induced Mouse Aortic Ring Microvessel Sprouting(A) Scheme of the mouse aorta ring experiments. Segments of aorta ring from 6-day-old mice were embedded in Matrigel and incubated with insulin and/or SB431542 or a neutralizing anti-TGF-β antibody or control IgG for 96 h.(B) Microvessel sprouting from aortic ring segments cultured *ex vivo* for 96 h with or without insulin in the presence or absence of SB431542 or anti-TGF-β antibody or control IgG. The microvessel growth in response to insulin is blocked by SB431542 or anti-TGF-β antibody in a mouse aorta ring assay. Representative images are shown.(C) Quantitative analysis of the *ex vivo* microvessel growth, measured as surface area to which vessels are extended. Error bars show ±SD. The experiments were repeated twice. Ctrl, control.

Discussion {#sec3}
==========

We previously reported that, in fibroblasts and epithelial cells, insulin induces, through Akt activation, the rapid mobilization of the TβRI and TβRII receptors from intracellular stores to the plasma membrane, thus enhancing TGF-β responsiveness and autocrine TGF-β signaling ([@bib10]). This raised the possibility that insulin-induced autocrine TGF-β signaling through Smad2 or Smad3 participates in insulin-induced gene responses, which was confirmed for a few selected genes in immortalized epithelial and fibroblast cell lines ([@bib10]). To evaluate the extent to which autocrine TGF-β signaling is integrated in the cellular response to insulin, we now studied the response of primary endothelial cells, a cell population that is directly exposed to insulin in circulation and whose angiogenic activation promotes the progression of a variety of diseases, including heart disease, diabetes-associated complications, fibroses, and cancer ([@bib3], [@bib28], [@bib56], [@bib87], [@bib91]). Our results allowed us to make conclusions of physiological relevance. (1) Insulin increases the cell surface levels of the TGF-β receptors, TβRI and TβRII, through Akt activation in human primary endothelial cells, thus enhancing autocrine TGF-β signaling. (2) Insulin-induced autocrine TGF-β signaling participates in the insulin-induced transcriptional response of human endothelial cells, including gene responses associated with angiogenesis. (3) Insulin-induced autocrine TGF-β signaling participates in insulin-induced angiogenic responses, including cell migration and endothelial network formation in culture and angiogenesis *ex vivo*. In summary, we report that enhanced autocrine TGF-β signaling in response to insulin is integral to insulin-induced angiogenesis.

Our analyses of the transcriptome and mRNA expression of individual genes in response to insulin supports the notion that autocrine TGF-β signaling through TβRI and Smads integrates into the overall endothelial gene expression response to insulin and the expression of some genes that are known to function in angiogenesis. Indeed, many insulin-induced gene responses were inhibited or attenuated when TGF-β-induced Smad activation was blocked. Among these genes, several encode transcription factors that contribute to the angiogenic response, e.g., *SRF* and *RUNX1* ([@bib32], [@bib30], [@bib31], [@bib50], [@bib60]), and their induction in response to insulin depended on autocrine TGF-β signaling. Even more striking is the contribution of autocrine TGF-β signaling to the activation of insulin-induced genes encoding secreted, pro-angiogenic cytokines. Specifically, the insulin-induced expression of angiopoietin-like 4, PDGF-A, and VEGF-A, all of which have been individually linked to induction of angiogenesis ([@bib2], [@bib6], [@bib16], [@bib42], [@bib46], [@bib67], [@bib85], [@bib88], [@bib92]), depended on TGF-β signaling. The induction of an angiogenic response to insulin has been functionally linked to activation of VEGF-A expression ([@bib71], [@bib75], [@bib110]), whereas the *VEGFA* gene is known to be directly induced by Smad3 in response to TGF-β ([@bib57], [@bib99]). Moreover, increased *ANGPTL4* expression is commonly seen in diabetic retinopathy ([@bib6]). Additionally, consistent with the notion that developing nerves and blood vessels use similar guidance mechanisms ([@bib4], [@bib15]), insulin induced changes in the expression of genes that participate in axon development and guidance ([@bib49], [@bib106], [@bib112]), such as *RHOB*, *SRF*, *RUNX1*, and also their induction was inhibited by blocking TGF-β signaling. This suggests that TGF-β signaling may also participate in insulin-induced changes in neurogenesis and neuronal guidance.

Insulin has been shown to stimulate angiogenesis, as assessed by cell culture and *ex vivo* and *in vivo* assays ([@bib28]). Subcutaneous injection of insulin in mice induces the development of new and extensively branched microvessels ([@bib25], [@bib71]), and topic insulin injection into foot ulcer wounds of diabetic patients promotes increased microvessel density that helps improve wound healing ([@bib114]). To define the contribution of autocrine TGF-β signaling in insulin-induced angiogenic responses, we used the pharmacological inhibitor SB431542 to block the TβRI kinase activity, and, consequently, TGF-β-induced Smad activation, and verified key results using another TβRI kinase inhibitor, LY2157299 (galunisertib), and/or specific pan-neutralizing anti-TGF-β monoclonal antibodies that prevent all TGF-β signaling. Generating primary HUVECs that stably and quantitatively lack TβRII or TβRI expression by small interfering RNA-mediated silencing was not feasible, and their silencing appears to be detrimental to these endothelial cells in culture. We used several assays that mimic major aspects of angiogenesis to assess the contribution of TGF-β signaling. Endothelial cell migration is essential to angiogenesis ([@bib61]), and migration in many different cell lines is known to be induced by insulin ([@bib10], [@bib52], [@bib72], [@bib98]). Our results indicate that insulin does not induce endothelial cell motility when TGF-β signaling is blocked and therefore that insulin-induced cell migration depends on autocrine TGF-β signaling. Furthermore, neutralizing anti-TGF-β antibody, SB431542, and LY2157299 prevented the insulin-induced increase of invasiveness, assessed in Transwell assays, although blocking TGF-β signaling enhanced the basal level of cell invasion. These results strongly suggest that TGF-β signaling participates in insulin-induced invasion. Since both kinase inhibitors block the TβRI kinase and thus prevent Smad2 and Smad3 activation, and the neutralizing 1D11 antibody prevents ligand binding to the receptors, and thus all ligand-induced TGF-β signaling pathways, differences in their effects may be anticipated and may highlight contributions of non-Smad signaling, e.g., of TGF-β-induced Akt-mTOR activation, which does not depend on the TβRI kinase activity ([@bib39]). Additionally, TGF-β1-induced ALK1 activation, which is not prevented by SB431542, may contribute to cell invasion, although insulin did not induce *ID1* expression in HUVECs ([Figures S3](#mmc1){ref-type="supplementary-material"}G and S3H), and inhibition of other kinases by SB431542, such as the ALK4 or ALK7 receptors, may also affect the outcome.

Based on our data, we surmise that TGF-β-induced Smad3 activation may participate in insulin-induced endothelial cell migration and invasion, in part through the induction of a mild or partial endothelial-mesenchymal transition (EndoMT) response. Indeed, insulin mildly induced the expression of *SNAI1* and *SNAI2*, which are known to drive EndoMT, are activated by Smad3 in response to TGF-β, and are required for endothelial cell invasion ([@bib63]). Insulin also induced increased fibronectin and N-cadherin expression and decreased VE-cadherin expression, which also mark EndoMT ([@bib37], [@bib89]). These EndoMT-defining responses were blocked when TGF-β signaling was blocked, highlighting the contribution of TGF-β signaling.

The endothelial network formation that we observed *in vitro* and in the mouse aortic ring assay provides strong evidence for participation of TGF-β signaling in the angiogenic responses to insulin. However, we did not see a repression of insulin-induced endothelial network formation when TGF-β signaling was inhibited using either SB431542 or the 1D11 antibody but instead observed an increase in basal and insulin-induced mesh and node formation. The enhanced formation of nodes and mesh-like structures, when TGF-β signaling is inhibited, is reminiscent of the SB431542-induced increase in VEGF-induced capillary sprouting by HUVECs in a spheroid angiogenesis assay ([@bib73]). Inhibition of TGF-β signaling strongly attenuated the ability of insulin to induce microvessel outgrowth from aortic ring segments *ex vivo*. This effect, similar to the requirement of TGF-β signaling for insulin-induced endothelial cell migration, highlights the contribution of autocrine TGF-β signaling to the insulin-induced angiogenic response. These observations are in line with the pro-angiogenic effects of TGF-β in the same microvessel outgrowth assay ([@bib115]) as well as in corneal and chicken chorioallantoic membrane angiogenesis assays ([@bib117], [@bib111]) and the requirement for TGF-β in murine vascular development ([@bib26]). Altogether, our data provide strong support for the participation of the insulin-induced increase in TGF-β responsiveness and autocrine TGF-β signaling in insulin-induced angiogenic responses.

We recognize that both ALK1 and TβRI/ALK5 signaling mediate TGF-β responses in endothelial cells and angiogenesis ([@bib36], [@bib62], [@bib73], [@bib76], [@bib84], [@bib95]), and it has been proposed that the activities from both type I receptors may balance each other in the control of angiogenesis ([@bib36], [@bib84]). Our results using the kinase inhibitors SB431542 and LY2157299 (galunisertib) and neutralizing anti-TGF-β antibodies revealed that TGF-β signaling, and specifically TGF-β signaling through TβRI/ALK5, contributes to insulin-induced angiogenic response and target gene expression. They are, however, not informative about a possible role of ALK1 in insulin-induced angiogenic responses. Such role may be suggested by the effect of the small molecule inhibitor LDN-193189, which targets ALK1 as well as related BMP type I receptors, on insulin-induced cell migration and invasion, although LDN-193189 did not affect insulin-induced *ID1* expression, a Smad1/5-directed target of activated ALK1 and other BMP type 1 receptors. Further research is required to address possible contributions of ALK1 or related BMP type I receptors in insulin-induced angiogenesis.

Although the insulin levels used in this study were higher than the normal insulin levels in blood, our findings may have substantial implications for the understanding of diabetes-associated complications in patients treated with insulin. Excessive formation of immature blood vessels is seen in association with tissue fibrosis, e.g., in the retina or kidney, in diabetic patients ([@bib29], [@bib77], [@bib82]), and, based on our findings, may result in part from the increased TGF-β responsiveness and the integration of enhanced autocrine TGF-β signaling in response to insulin. Furthermore, many diabetes-associated complications are associated with fibrosis ([@bib7]), which is driven by increased TGF-β signaling ([@bib43], [@bib63], [@bib103]). Accordingly, these fibrotic lesions show increased Smad3 activation ([@bib48], [@bib55]). As we reported before, the increased TGF-β signaling may be initiated by high glucose- or insulin-induced increases in TGF-β responsiveness ([@bib10], [@bib109]). Our findings may also be relevant in the context of cancer progression, since carcinomas depend on tumor angiogenesis. Higher rates of certain cancer types have been associated with type 2 and type 1 diabetes and insulin plasma levels ([@bib8], [@bib33], [@bib34], [@bib47], [@bib54]). Additionally, tumor cells themselves often show an increased expression of insulin-related growth factor (IGF) 1 ([@bib90]), which acts through insulin and IGF-1 receptors, similar to insulin ([@bib105]). The extent to which the insulin-induced upregulation of TGF-β responsiveness contributes to diabetes- or cancer-associated angiogenesis is worth consideration.

Limitations of the Study {#sec3.1}
------------------------

We showed that insulin-induced autocrine TGF-β signaling contributes to many aspects of angiogenesis, in cell culture, *ex vivo*, and in zebrafish. Owing to technical limitations and, in the case of humans, to ethical considerations, the importance of insulin-induced autocrine TGF-β signaling in these same aspects of angiogenesis may not be defined in the whole organism *in vivo*, i.e., in mice or humans. Our RNA-seq study showed integration of TGF-β signaling in the insulin-regulated expression of many genes that are associated with angiogenesis. Levels of RNA may serve as useful indication of their regulation but are not necessarily predictive of the protein levels. Further study is needed to examine the abundance of the proteins expressed by genes associated with angiogenesis in endothelial cells. In vertebrates, the integrity and functions of endothelial cells that line the vessel wall are defined through functional contacts with many cells, including pericytes, smooth muscle cells, and blood cells. Our study focuses on the endothelial cells, with less focus on these other cells that provide additional signals to the endothelial cells. Lastly, consistent with most if not all studies in cell culture, insulin used in this study was used at higher levels than those that are seen as normal physiological levels in circulation.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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Document S1. Transparent Methods and Figures S1--S4Table S1 Enrichment Analysis of Gene Ontology (GO) for Biological Process Terms in HUVECs, Comparing Insulin Treatment and Control Treatment, Related to Figure 2Data comparing insulin treatment and control treatment are organized by lowest adjusted p-value and p \< 0.05 was considered as a statistically significant difference.Table S2. Enrichment Analysis of Gene Ontology (GO) for Biological Process Terms in HUVECs Comparing SB431542 Treatment and Control Treatment, Related to Figure 2Data comparing SB431542 treatment and control treatment are organized by lowest adjusted p-value, and p \< 0.05 was considered as a statistically significant difference.Table S3. Enrichment Analysis of Gene Ontology (GO) for Biological Process Terms in HUVECs Comparing Insulin + SB431542 Treatment and Insulin Treatment, Related to Figure 2Data comparing insulin + SB431542 treatment and insulin treatment are organized by lowest adjusted p-value, and p \< 0.05 was considered to indicate a statistically significant difference.Table S4. Ingenuity Pathway Analysis (IPA): Diseases/Functions Analysis on mRNA Transcripts of Different Groups, Related to Figure 2A positive or negative z-score value indicates that a function is predicted to be increased or decreased when compared to the indicated group.Table S5. Primer Sequences Used in This Study, Related to Figure 1, 2, 3, and 5Primer sequences are given in 5′ to 3′ direction.
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